Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Cagrilintide

Stage Phase 3Stale

Sponsor Novo Nordisk A/S

Route injection

Class Amylin

Mechanism long-acting amylin analogue

Sources

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT07220759

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 330. Conditions Overweight; Obesity; Type 2 Diabetes. This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Whic

ClinicalTrials.gov NCT07220759 protocol and results modules

registry, as of 2026-08-06Stale

https://clinicaltrials.gov/study/NCT07220642

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity; Overweight. This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment partici

ClinicalTrials.gov NCT07220642 protocol and results modules

registry, as of 2026-08-25Stale

https://clinicaltrials.gov/study/NCT06719011

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 178. Conditions Obesity; Overweight. This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine N

ClinicalTrials.gov NCT06719011 protocol and results modules

registry, as of 2026-05-15Stale

https://clinicaltrials.gov/study/NCT07557953

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 120. Conditions Overweight; Obesity. The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is th

ClinicalTrials.gov NCT07557953 protocol and results modules

registry, as of 2026-10-19Stale

https://clinicaltrials.gov/study/NCT07607587

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 114. Conditions Obesity; Overweight. The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (t

ClinicalTrials.gov NCT07607587 protocol and results modules

registry, as of 2024-11-01Stale

https://clinicaltrials.gov/study/NCT05804162

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 107. Conditions Obesity. The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo. To confirm the sensitivity of the methodology, the drug moxifloxacin is also compared to a placebo in 2 treatment arms. Cagrilintide is be

ClinicalTrials.gov NCT05804162 protocol and results modules

registry, as of 2026-04-13Stale

https://clinicaltrials.gov/study/NCT07411560

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 100. Conditions Overweight; Obese. This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other

ClinicalTrials.gov NCT07411560 protocol and results modules

registry, as of 2026-09-04Stale

https://clinicaltrials.gov/study/NCT07605052

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 50. Conditions Overweight; Obesity. The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance.

ClinicalTrials.gov NCT07605052 protocol and results modules

publication, as of 2026-08-18Stale

https://pubmed.ncbi.nlm.nih.gov/42608559/

trials. To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals. A systema

PMID 42608559

Studies

RENEW 2

Registry NCT07220759

Phase Phase 3

Status Active, not recruiting

Enrollment 330

Start 2025-11-05

Primary completion 2027-05-12

Study completion 2027-06-30

Catalyst Primary completion. 2027-05-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide

Regimen once weekly

Weeks 64

Comparator placebo

Population Overweight; Obesity; Type 2 Diabetes

Placebo

Regimen once weekly

Weeks 64

Population Overweight; Obesity; Type 2 Diabetes

RENEW 1

Registry NCT07220642

Phase Phase 3

Status Active, not recruiting

Enrollment 300

Start 2025-11-05

Primary completion 2027-05-11

Study completion 2027-06-29

Catalyst Primary completion. 2027-05-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide

Regimen once weekly

Weeks 64

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Weeks 64

Population Obesity; Overweight

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Registry NCT06719011

Phase Phase 1

Status Completed

Enrollment 178

Start 2024-12-03

Primary completion 2026-07-20

Study completion 2026-07-20

Catalyst Primary completion. 2026-07-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A: NNC0174-1213 (SD1-SD5)

Comparator placebo

Population Obesity; Overweight

Part A: Cagrilintide (SDA and SDB)

Comparator placebo

Population Obesity; Overweight

Part A: Placebo

Population Obesity; Overweight

Part B: NNC0174-1213 (MD1-MD5)

Comparator placebo

Population Obesity; Overweight

Part B: Cagrilintide (MDA)

Comparator placebo

Population Obesity; Overweight

Part B: Placebo

Population Obesity; Overweight

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Registry NCT07557953

Phase Phase 1

Status Recruiting

Enrollment 120

Start 2026-04-30

Primary completion 2027-04-13

Study completion 2027-04-13

Catalyst Primary completion. 2027-04-13. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide

Regimen once weekly

Weeks 30

Comparator placebo

Population Overweight; Obesity

Placebo Cagrilintide

Regimen once weekly

Weeks 30

Population Overweight; Obesity

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Registry NCT07607587

Phase Phase 1

Status Recruiting

Enrollment 114

Start 2026-05-29

Primary completion 2027-11-19

Study completion 2027-11-19

Catalyst Primary completion. 2027-11-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Registry NCT05804162

EudraCT 2022-002357-25

Phase Phase 1

Status Completed

Enrollment 107

Start 2023-04-12

Primary completion 2023-08-12

Study completion 2023-09-18

Cagrilintide (Arm 1)

Regimen once weekly

Weeks 17

Comparator placebo

Population Obesity

Cagrilintide Placebo (Arm 2A)

Regimen once weekly

Weeks 17

Population Obesity

Cagrilintide Placebo (Arm 2B)

Regimen once weekly

Weeks 17

Population Obesity

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Registry NCT07411560

Phase Phase 1

Status Recruiting

Enrollment 100

Start 2026-02-09

Primary completion 2027-01-26

Study completion 2027-01-26

Catalyst Primary completion. 2027-01-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide

Regimen weekly

Population Overweight; Obese

Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide

Regimen weekly

Population Overweight; Obese

Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide

Regimen weekly

Population Overweight; Obese

Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide

Regimen weekly

Population Overweight; Obese

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

Registry NCT07605052

Phase Phase 1

Status Completed

Enrollment 50

Start 2026-05-20

Primary completion 2026-08-19

Study completion 2026-08-19

Catalyst Primary completion. 2026-08-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide B

Regimen once weekly

Weeks 14

Population Overweight; Obesity

Cagrilintide D

Regimen once weekly

Weeks 14

Population Overweight; Obesity